Vitae Pharmaceuticals (VTAE) Tops Q4 EPS by 10c

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q4 EPS of ($0.52), $0.10 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $92.09 thousand versus the consensus estimate of $120 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c